EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
BioNTech to build vaccine plant in Singapore
4
published : 10 May 2021 at 14:20
4 FILE PHOTO: Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada Jan 4, 2021. (Reuters)
Covid jab maker BioNTech said Monday it would build a southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year.
Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world, said BioNTech chief executive Ugur Sahin.
-
-
Speakers
-
German Chancellor Merkel said to be under pressure to lay out a path to ease Germany’s coronavirus lockdown
-
France Fin Min Le Maire stated that he was not concerned about the recent increase in borrowing rates. Govt had spent €16B of the stimulus plan. Would not raise taxes or tax household savings
-
BOJ said to be prepared to defend Yield Curve (YCC) range before its March policy review. BOJ had no pre-set level for stopping yield rise and would depend on the speed of gains. Could act before yield hits 0.3%
-
Currencies/Fixed Income